CASI Pharmaceuticals, Inc., 2026-02-26
An SEC Form D private-offering notice from Beijing, a $5,000,000 filer-stated offering target in Biotech. Filed 2026-02-26. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Nasdaq listed biopharmaceutical company developing therapeutics including an anti CD38 antibody for transplant rejection, with China operations run through a Beijing subsidiary
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Conexeu Sciences Inc., 2026-02-27, $1.1M, Reno, NV
- Linnaeus Therapeutics, Inc., 2026-02-27, $10M, Haddonfield, NJ
- CoRegen, Inc., 2026-02-26, $13.5M, Houston, TX
- Onyx Bio, Inc., 2026-02-26, $8M, Berkeley, CA
- GeneCapture, Inc., 2026-02-26, $3M, Huntsville, AL
- Quarry Heme, Inc, 2026-02-25, $13.5M, New Haven, CT
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.